




# AUGUST AND 8M2024 BUSINESS UPDATES

**IMEXPHARM CORPORATION** 


## Continued M-o-M growth in revenue and earnings, driven by ETC channel



- We continued to experience monthover-month growth, though yearover-year growth has slowed due to the strong performance in August 2023.
- ETC maintained its strong revenue growth trajectory, achieving a 44% year-over-year increase.
- In OTC, we expanded our retail network and saw sustained growth in sales through key chains, up 53% year-over-year. However, a decline in sales to distributors and retail pharmacies resulted in an overall decrease in OTC revenue, reflecting OTC market challenges



## Outperforming market in both ETC and OTC; endeavor to align year-end targets





 We have achieved VND 1,344 billion in net revenue, representing 57% of our annual target. We are confident in delivering our target revenue for the year as revenue tends to skew towards the final quarter of every year

- Given ongoing challenges in the OTC market, we are currently making appropriate adjustments including sales and marketing program optimization to align year-end bottom line targets
- Both ETC and OTC are outperforming market



## Stock performance and business highlights





#### Dec 29-Jan 29-Feb 31-Mar 30-Apr 31-May 30-Jun 31-Jul 31-Aug

	IMP	DHG	TRA	DHT	DBD
YTD avg. daily trading volume	61,797	25,038	2,176	126,863	159,491
YTD stock performance	96%	<b>A</b> 7%	(9%)	219%	(3%)
Daily trading volume in 8M24 vs. 2023	340%	(24%)	(9%)	<b>5</b> 1%	7%
Market cap (VND billion)	7,662	14,092	3,208	5,912	3,929

#### 1. Stock bonus issuance execution

- Ex-right date: September 17, 2024
- Payment ratio: 100% (1:1)
- Post-issuance charter capital: VND 1,540 bn

#### 2. Organizational restructuring

- To improve supply chain management and customer satisfaction
- To strengthen the processes between Finance team and Procurement team

### 3. Attend C-level forum in Pharma in Shanghai

- To showcase the growth potential of the
  Vietnam pharmaceutical market to key industry
  stakeholders and potential investors.
- To continue engaging with international investors



## Disclaimer

The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter.

IMP is exempt from any liability for any losses and damages relating to the use of this document as well as other inaccurate, incomplete, or untimely information about IMP. IMP has the right to change and update information in our newsletters at any time without prior notice.



#### **Contact Us**

Imexpharm Investor Relations Team Office: Floor 24, Flemington Tower, 182 Le Dai Hanh Street, Ward 15, District 11, HCMC Email: <u>ir@imexpharm.com</u>







For further discussion, please contact our IR team

ir@imexpharm.com